Dated: Jul 14, 2022
Publication Name: Cancer Science
Citations : Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity
Trastuzumab- induced cardiotoxicity interferes with continued treatment in approxi-mately 10% of patients with ErbB2- positive breast cancer, but its mechanism has not been fully elucidated. In this study, we recruited trastuzumab- treated patients with ≥30% reduction in left ventricular ejection fraction (SP) and noncardiotoxic patients (NP). From each of these patients, we established three cases of induced pluripotent stem cell- derived cardiomyocytes (pt- iPSC- CMs). Reduced contraction and relaxation velocities following trastuzumab treatment were more evident in SP pt- iPSC- CMs than NP pt- iPSC- CMs, indicating the cardiotoxicity phenotype could be replicated.
Contributors: Ritsuko Sasaki, Nagomi Kurebayashi, Hidetaka Eguchi, Yoshiya Horimoto, Takahiro Shiga, Sakiko Miyazaki, Taku Kashiyama, Wado Akamatsu and Mitsue Saito